“The encouraging secondary endpoint data suggest that further studies may help to uncover the potential role of OXN PR in this patient population,” Professor Trenkwalder said in a news release. “This study adds to the very limited knowledge base on the efficacy and safety of opioid-based treatment of patients with Parkinson’s disease suffering from complex pain.”

Overall, nearly the same proportion of patients taking OXN PR or placebo experienced adverse events (65% vs. 70%), including treatment-related adverse events (57% vs. 57%) and serious adverse events (5% vs. 6%). Treatment-related nausea (17% vs. 9%) and constipation (17% vs. 6%) was more common in the OXN PR group compared to those taking placebo.

Despite not meeting the primary endpoint, the study results imply a positive role for OXN PR for Parkinson’s pain, and the researchers encourage further research to be conducted on OXN PR in this population.

References

  1. Trenkwalder C et al. Lancet Neurol. 2015; doi:10.1016/S1474-4422(15)00243-4.
  2. Mundipharma news release

This article originally appeared on Neurology Advisor